Phenotypeca

Executive Summary

Phenotypeca is a UK-based synthetic biology company founded in 2013 that specializes in engineering high-performance microbial strains for recombinant protein production. By leveraging evolution and genetic diversity, the company develops scalable, low-cost strains for biosimilars, therapeutic biologics, and peptides. Phenotypeca operates a proprietary strain licensing model and offers custom strain development services, positioning itself as a enabler in the biologics manufacturing value chain. Despite being private with undisclosed funding, the company addresses a critical need for cost-effective production of complex proteins, aligning with industry trends toward precision fermentation and biologics accessibility.

Upcoming Catalysts (preview)

• Q3 2026First commercial licensing deal for a biosimilar strain40% success
• Q2 2026Publication of performance data in a peer-reviewed journal70% success
• Q4 2026Series A funding round announcement50% success